Skip to main content
HR 5350 113th Congress House Environmental Protection Consumer affairs Drug safety, medical device, and laboratory regulation Hazardous wastes and toxic substances Health promotion and preventive care Infectious and parasitic diseases Marketing and advertising Medical research Metals Pest management Retail and wholesale trades

Infection Reduction Labeling Act of 2014

Introduced: July 31, 2014 Introduced by: Latta, Robert E. Republican · Ohio See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 113th Congress ended
It never became law before the 113th Congress (2013–2014) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 22, 2014
Referred to the Subcommittee on Horticulture, Research, Biotechnology, and Foreign Agriculture.
Aug 1, 2014
Referred to the Subcommittee on Health.
Jul 31, 2014
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Agriculture, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 31, 2014
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Infection Reduction Labeling Act of 2014 - Amends the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) to authorize solid antimicrobial copper alloys, and products made from such alloys, to be marketed, distributed, or sold with labels about their infection reduction and control efficacy if the antimicrobial claims made on the label are consistent with the results of federally-funded clinical trials finding: (1) greater than 25% reductions in infection rate or 50% reductions in microbial burden, or (2) statistically significant reductions in infection rate or microbial burden.

Waives alloys from requirements to submit or review efficacy data related to the antimicrobial claims if the claims are consistent with the results of the trials.

Sets forth an alternative process to modify the labeling of an alloy.

Amends the Federal Food, Drug, and Cosmetic Act to exclude a product that is made from the alloy and has the antimicrobial labeling from regulation and treatment as a drug or device .

What's happening now September 22, 2014

Referred to the Subcommittee on Horticulture, Research, Biotechnology, and Foreign Agriculture.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5350: Infection Reduction Labeling Act of 2014. 113th Congress. Open America. https://openamerica.io/bill/113-HR-5350/
MLA
"H.R. 5350: Infection Reduction Labeling Act of 2014." 113th Congress, 2026, Open America, https://openamerica.io/bill/113-HR-5350/.
Bluebook (legal)
H.R. 5350, 113th Cong. (2026), https://openamerica.io/bill/113-HR-5350/.
Markdown link
[H.R. 5350: Infection Reduction Labeling Act of 2014](https://openamerica.io/bill/113-HR-5350/)
Report a problem